Friday, October 30, 2009

CDC’s Weekly Flu Indicators

 

# 3914

 

Just posted (1:30pm EDT) on the CDC.gov/h1n1flu  website is this week’s flu situation update.    Later today we’ll get a more detailed FluView report.  This data is for the week of October 18-24th.

 

As I reported yesterday, 22 pediatric influenza deaths were added last week, 19 laboratory confirmed as being H1N1.

 

 

 

2009 H1N1 Flu: Situation Update

October 30, 2009, 1:30 PM ET

U.S. Situation Update

Weekly Flu Activity Estimates
Map of flu activity in the U.S. for week ending October 17, 2009. Select to view full-sized map.

U.S. Patient Visits Reported for Influenza-like Illness (ILI)
Graph of U.S. patient visits reported for Influenza-like Illness (ILI).

U.S. Influenza-like Illness (ILI) Reported by Regions
Map of U.S. Influenza-like Illness (ILI)<br />
Reported by Regions.

U.S. Influenza and Pneumonia-Associated Hospitalizations and Deaths from August 30 to October 24, 2009

International
Situation Update

Map of International
Activity Estimates
(Including 2009 H1N1 Flu)

This picture depicts a map of the world that shows the co-circulation of 2009 H1N1 flu and seasonal influenza viruses. The United States, Canada, Europe, Australia, Kenya, China and Hong Kong (China) are depicted. There is a pie chart for each that shows the percentage of laboratory confirmed influenza cases that have tested positive for either 2009 H1N1 flu or other influenza subtypes. The majority of laboratory confirmed influenza cases reported in the United States, Canada, Europe, Australia, Kenya, China and Hong Kong (China) have been 2009 H1N1 flu.

Key Flu Indicators

October 30, 2009, 1:30 PM

Each week CDC analyzes information about influenza disease activity in the United States and publishes findings of key flu indicators in a report called FluView. During the week of October 18-24, 2009, a review of the key indictors found that influenza activity continued to increase in the United States from the previous week. Below is a summary of the most recent key indicators:

  • Visits to doctors for influenza-like illness (ILI) increased steeply since last week in the United States, and overall, are much higher than what is expected for this time of the year. ILI activity now is higher than what is seen during the peak of many regular flu seasons.
  • Total influenza hospitalization rates for laboratory-confirmed flu are climbing and are higher than expected for this time of year. Hospitalization rates continue to be highest is younger populations with the highest hospitalization rate reported in children 0-4 years old.
  • The proportion of deaths attributed to pneumonia and influenza (P&I) based on the 122 Cities Report has increased and has been higher than what is expected at this time of year for four weeks now. In addition, 22 flu-related pediatric deaths were reported this week; 19 of these deaths were confirmed 2009 H1N1, and three were influenza A viruses, but were not subtyped. Since April 2009, CDC has received reports of 114 laboratory-confirmed pediatric 2009 H1N1 deaths and another 12 pediatric deaths that were laboratory confirmed as influenza, but where the flu virus subtype was not determined.
  • Forty-eight states are reporting widespread influenza activity at this time. They are: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. This many reports of widespread activity are unprecedented during seasonal flu.
  • Almost all of the influenza viruses identified so far are 2009 H1N1 influenza A viruses. These viruses remain similar to the virus chosen for the 2009 H1N1 vaccine, and remain susceptible to the antiviral drugs oseltamivir and zanamivir with rare exception.